Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) Overview 6 Therapeutics Development 7 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Products under Development by Stage of Development 7 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Products under Development by Therapy Area 8 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Products under Development by Indication 9 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Products under Development by Companies 13 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Companies Involved in Therapeutics Development 22 Dompe Farmaceutici S.p.A. 22 PharmatrophiX, Inc. 23 Sanofi 24 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Drug Profiles 25 Drugs to Antagonize P75 Neurotrophin Receptor for Alzheimer's Disease - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 LEVI-04 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 LM11A-31BHS - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 SAR-244181 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Dormant Projects 32 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Discontinued Products 34 Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Featured News & Press Releases 35 Dec 02, 2015: rhNGF, the Dompe Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency 35 Nov 22, 2014: Italian research at the SOI Congress: focus on therapeutic prospects of NGF, the innovative molecule developed on the basis of the studies by Rita Levi Montalcini in ophthalmology 36 Sep 25, 2014: EuCornea: Dompe wins the “Best Poster Award” for its preliminary data concerning the use of rhNGF in the treatment of neurotrophic keratitis 37 Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 38 Apr 03, 2014: First Patient is Enrolled in Lumos Study. Objective: to Evaluate Safety and Potential Efficacy of rhNGF in the Treatment of Retinitis Pigmentosa 39 Sep 11, 2013: Dompé Announces the Food and Drugs Administration Has Granted Orphan Drug Designation to its rhNGF-based Treatment for Retinitis Pigmentosa 40 Jul 01, 2013: Dompé Announces the EMA Has Granted Orphan Drug Designation to Its rhNGF-Based Treatment for Retinitis Pigmentosa 40 Feb 14, 2013: Dompe Announces Enrollment of First Patient in First International Clinical Trial of rhNGF for Treatment of Neurotrophic Keratitis 42 Sep 07, 2012: Dompé Initiates Phase I Clinical Trial On Use Of Recombinant Human Nerve Growth Factor For Treating Neurotrophic Keratitis 42 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45

List of Tables Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 17 Number of Products by Stage and Route of Administration, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 21 Pipeline by Dompe Farmaceutici S.p.A., H2 2016 22 Pipeline by PharmatrophiX, Inc., H2 2016 23 Pipeline by Sanofi, H2 2016 24 Dormant Projects, H2 2016 32 Dormant Projects (Contd..1), H2 2016 33 Discontinued Products, H2 2016 34 List of Figures Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Top 10 Indication, H2 2016 9 Comparative Analysis by Early Stage Products, H2 2016 12 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Mechanism of Actions, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Routes of Administration, H2 2016 18 Number of Products by Stage and Routes of Administration, H2 2016 18 Number of Products by Molecule Types, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 20

Dompe Farmaceutici S.p.A. PharmatrophiX, Inc. Sanofi